

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

(Convertible Bonds Code: 40546)

ADJUSTMENT TO CONVERSION PRICE OF THE CONVERTIBLE BONDS

References are made to the announcements (the “**CB Announcements**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) dated January 8, 2021, January 22, 2021, January 24, 2021, January 25, 2021 and January 22, 2024 and the monthly return of the Company dated January 5, 2023 in relation to the US\$600 million zero coupon convertible bonds due 2026. Capitalized words and expressions used herein have the same meanings as those defined in the CB Announcements.

In accordance with the terms and conditions of the Convertible Bonds, an adjustment will be made to the Conversion Price on the date immediately after the record date for the payment of the final dividend for the year ended December 31, 2023. The Conversion Price will be adjusted from HK\$59.33 per Share to HK\$58.13 per Share with effect from June 26, 2024. Save for the above Conversion Price adjustment, all other terms and conditions of the Convertible Bonds remain unchanged.

As at the date of this announcement, the outstanding principal amount of the Convertible Bonds is US\$5,378,000. The maximum number of Conversion Shares that will be issued upon conversion of all the outstanding Convertible Bonds at the current Conversion Price and the adjusted Conversion Price is 702,765 Shares and 717,273 Shares (based on the fixed exchange rate of HK\$7.7529 = US\$1.00), respectively.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, June 13, 2024

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.